eribulin

Eribulin (B1939) is a nonpaclitaxel microtubule kinetic inhibitor with anticancer activity that inhibits polymerization of microtubule protein subunits by preventing lengthening and shortening of microtubules during cell division.Eribulin is used in the study of metastatic breast cancer and solid tumors.

Eribulin mesylate (E7389 mesylate) (E7389 mesylate) inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used in the treatment of metastatic breast cancer.

Eribulin Mesylate (GMP) refers to the GMP grade reagents of Eribulin Mesylate. Eribulin mesylate (E7389 mesylate) (E7389 mesylate) inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used in the treatment of metastatic breast cancer.

Mal-PEG2-VCP-Eribulin is a chemotherapeutic compound comprising an antibody-drug conjugate (ADC) linker (Mal-PEG2-VCP) and the microtubule inhibitor Eribulin[1]. This compound uniquely targets microtubules, offering a novel approach to cancer treatment. Eribulin is specifically utilized in creating targeted Eribulin-based drugs for antibody conjugates[1].

VCP-Eribulin, an Eribulin-based drug for antibody conjugates[1], combines the VCP (ADCs linker) with Eribulin, a distinct microtubule inhibitor used in cancer treatments[2].

O-Me Eribulin, a derivative of Eribulin, serves as a cytotoxin for ADC (Antibody-Drug Conjugate) synthesis. It demonstrates the capability to inhibit the cell viability of SKBR3, MDA-MB-468, and A549 cells, with respective IC50 values of 0.2052, 0.1827, and 0.5151 nM. O-Me Eribulin is also utilized in cancer research.

VcMMAE-Eribulin is a (Drug-Linker Conjugates for ADC) composed of the linker and cytotoxic molecules MMAE and Eribulin. This conjugate is used in the synthesis of ADCs.

Deruxtecan-Eribulin is a Drug-Linker Conjugate for ADC comprised of a linker and two cytotoxic molecules: Exatecan (a DNA topoisomerase I inhibitor) and Eribulin (a microtubule inhibitor). This compound is utilized in the synthesis of ADCs.

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a potent antitumor ADC drug-linker conjugate utilizing Eribulin, an anti-microtubule agent, connected through the Mal-(CH2)5-Val-Cit-PAB linker.

Eribulin-GGFG (Compound GGFG) is a drug-linker conjugate for antibody-drug conjugates (ADCs). Comprised of the cytotoxic agent exatecan and a connecting linker, it facilitates the synthesis of ADCs [1].

Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA). This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-eribulin through reduced interchain disulfide bonds, with an agent-to-antibody ratio of 4.0, demonstrating potent antitumor activity against FRA-positive cells in vitro.